Logo

Optimizing Antibody Based Therapeutics

  • About Us

    • Home
    • Press Release
    • Investor Relations
  • Research

    • Focus Areas
  • Pipeline for AME-133v

    • Antibody Optimization and Design
    • Oncology
    • Rheumatology
    • Preclinical Research
  • Careers

    • Career Opportunities
  • Contact

    • Contact Us
Banner
About Us

Mentrik Biotech, LLC is a private biopharmaceutical company that was incorporated in December 2010 and is headquartered in Dallas, TX. The goal of Mentrik Biotech is to optimize oncology-based therapeutics to treat patients with significant unmet medical need.

Mentrik is developing AME-133v, a humanized, next-generation anti-CD20 monoclonal antibody. It is engineered for enhanced affinity to CD20 and increased antibody-dependent cell-mediated cytotoxicity (ADCC), and designed for improved treatment for low-affinity FcγRIIIa polymorphisms. Phase I/II trials in follicular lymphoma have been conducted in the US and Japan, and a Phase I trial in US rheumatoid arthritis patients. Continued Phase III development in relapsed follicular lymphoma patients is underway. Many patients relapse following current available treatments and a significant need for new effective treatment exists. Additional development in other oncology and rheumatology indications will also be pursued.



Our Vision

Mentrik Biotech aims to develop convenient, potent and cost-effective anti-cancer molecules to enhance treatment options for patients and fulfill unmet therapeutic needs.


By utilizing engineered antibodies and next-generation molecules, Mentrik seeks to fulfill an unmet need in patient therapeutics by enhancing treatment options and optimizing clinical benefit. By developing more potent therapeutics, Mentrik can facilitate improved treatment through less frequent dosing, decreased drug administration, and create subcutaneous formulations for easier patient administration.


Mentrik also aims to support healthcare in developing countries, supplying superior antibodies to patients where treatment is lacking or non-existent at a very low cost.

More
Research

The development efforts for AME-133v, an anti-CD20 monoclonal antibody, are focussed toward Oncology and Autoimmune Diseases.

Pipeline for AME-133V

AME-133v is a humanized, next-generation IgG1 monoclonal antibody engineered that was optimized through protein engineering for both..

Join Our Team

MENTRIK Biotech, LLC encompasses a dynamic and diverse team composed of individuals with long-term drug development experience and young, energetic professionals..

Poster

 



MENTRIK Biotech, LLC

info@mentrik.com                     (214) 593 0500
5420 LBJ Freeway Suite 410, Dallas, Texas - 75240